Literature DB >> 22249977

Impact of codon 72 Arg > Pro single nucleotide polymorphism in TP53 gene in the risk of kangri cancer: a case control study in Kashmir.

Arshad A Pandith1, Nighat P Khan, Nargis Rashid, Niyaz Azad, Inam Zaroo, Adil Hafiz, Mushtaq A Siddiqi.   

Abstract

Kangri cancer found only in Kashmir (north India) is a unique thermally induced squamous cell carcinoma of the skin that develops because of chronic and persistent irritation due to the use of a kangri (a brazier) by the Kashmiri people to combat the chilling cold temperature during winter. Being unique to this region, the molecular etiology of the invasive kangri cancer is not known fully. The TP53 gene, codon 72 polymorphism (Arg72Pro), has been found to be associated with cancer susceptibility but has not been investigated in kangri cancer risk. A case control study was conducted to find the genotype distribution of TP53 Arg72Pro SNP and to elucidate the possible role of this SNP as risk factor in kangri cancer development. Using the polymerase chain reaction-restriction fragment length polymorphism approach, we tested the genotype distribution of 106 kangri cancer patients in comparison with 200 cancer-free controls from the same geographical region. A significant difference was observed between the control and kangri cancer patients with odds ratio = 2.02 and 95% confidence interval = 1.2-3.3 (p = 0.01). Interestingly, the proline form was abundantly observed in advanced-grade tumors (p < 0.05). We also found a significant association of the variant allele (GC + CC) with male subjects and patients >45 years of age (p < 0.05). Thus, it is evident from our study that Arg72Pro SNP is implicated in kangri cancer and that the rare, proline-related allele is connected with higher susceptibility to kangri cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22249977     DOI: 10.1007/s13277-012-0318-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  37 in total

1.  A common polymorphism acts as an intragenic modifier of mutant p53 behaviour.

Authors:  M C Marin; C A Jost; L A Brooks; M S Irwin; J O'Nions; J A Tidy; N James; J M McGregor; C A Harwood; I G Yulug; K H Vousden; M J Allday; B Gusterson; S Ikawa; P W Hinds; T Crook; W G Kaelin
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

2.  On a turf (peat) fire cancer: malignant change superimposed on erythema ab igne.

Authors:  F Cross
Journal:  Proc R Soc Med       Date:  1967-12

3.  Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population.

Authors:  Arshad A Pandith; Zafar A Shah; Nighat P Khan; Roohi Rasool; Dil Afroze; Adfar Yousuf; Saleem Wani; Mushtaq Siddiqi
Journal:  Cancer Genet Cytogenet       Date:  2010-12

4.  p53 polymorphic variants at codon 72 exert different effects on cell cycle progression.

Authors:  David Pim; Lawrence Banks
Journal:  Int J Cancer       Date:  2004-01-10       Impact factor: 7.396

5.  Is p53 polymorphism maintained by natural selection?

Authors:  G Beckman; R Birgander; A Själander; N Saha; P A Holmberg; A Kivelä; L Beckman
Journal:  Hum Hered       Date:  1994 Sep-Oct       Impact factor: 0.444

6.  P53 germ line haplotypes associated with increased risk for colorectal cancer.

Authors:  A Själander; R Birgander; L Athlin; R Stenling; J Rutegård; L Beckman; G Beckman
Journal:  Carcinogenesis       Date:  1995-07       Impact factor: 4.944

7.  Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma.

Authors:  Venkat R Katkoori; Xu Jia; Chandrakumar Shanmugam; Wen Wan; Sreelatha Meleth; Harvey Bumpers; William E Grizzle; Upender Manne
Journal:  Clin Cancer Res       Date:  2009-04-01       Impact factor: 12.531

8.  Kangri-Burn Epithelioma in Kashmir.

Authors:  Arthur Neve
Journal:  Ind Med Gaz       Date:  1900-03

9.  Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer.

Authors:  Sandra Costa; Daniela Pinto; Deolinda Pereira; Helena Rodrigues; Jorge Cameselle-Teijeiro; Rui Medeiros; Fernando Schmitt
Journal:  BMC Cancer       Date:  2008-01-29       Impact factor: 4.430

10.  The R72P P53 mutation is associated with familial breast cancer in Jewish women.

Authors:  T Ohayon; R Gershoni-Baruch; M Z Papa; T Distelman Menachem; S Eisenberg Barzilai; E Friedman
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

View more
  7 in total

1.  No evidence of correlation between p53 codon 72 G > C gene polymorphism and cancer risk in Indian population: a meta-analysis.

Authors:  Raju K Mandal; Suraj S Yadav; Aditya K Panda
Journal:  Tumour Biol       Date:  2014-05-28

2.  The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases.

Authors:  Surong Hu; Lianying Zhao; Jingting Yang; Miao Hu
Journal:  Tumour Biol       Date:  2013-12-11

3.  Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk.

Authors:  Long Lv; Ping Wang; Xiaoqing Zhou; Beicheng Sun
Journal:  Tumour Biol       Date:  2013-04-06

4.  The association between polymorphism of P53 codon 72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3704 cases.

Authors:  Surong Hu; Lianying Zhao; Jingting Yang; Miao Hu
Journal:  Meta Gene       Date:  2013-10-30

Review 5.  Role of Sex in the Therapeutic Targeting of p53 Circuitry.

Authors:  Francesca Mancini; Ludovica Giorgini; Emanuela Teveroni; Alfredo Pontecorvi; Fabiola Moretti
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

6.  Arg72Pro polymorphism of TP53 gene and the risk of skin cancer: a meta-analysis.

Authors:  Jun Ye; Xiao-Fen Li; Yong-Dong Wang; Ying Yuan
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

Review 7.  Novel medical strategies combating nonmelanoma skin cancer.

Authors:  Prasan R Bhandari; Varadraj V Pai
Journal:  Indian J Dermatol       Date:  2014-11       Impact factor: 1.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.